

To: Russell White <whiter@api.org>
From: michael.g.bird@exxonmobil.com <michael.g.bird@exxonmobil.com>
Cc: Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com>
Bcc:
Received Date: 2006-11-13 20:50:34 GMT
Subject: Re: Shanghai Health Study - new budget estimate

Russ, I know that Stuart is working Otto Wong's needs, but I believe there was mention of some separate contract or support for Dr Fu ? If so is that part of Otto's contract or a separate EA activity ? Just want to make sure that everything is covered.
Michael

Michael G. Bird, PhD., DABT
Toxicology & Environmental Sciences Division,
ExxonMobil Biomedical Sciences, Inc.
1545 Route 22 East
P.O. Box 971
Annandale, New Jersey 08801-0971
tel: 908 730 1060
fax: 908 730 1199
Email: michael.g.bird@exxonmobil.com

This document and all information contained within this electronic message may be privileged, confidential and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited.

"Russell
White"
<whiter@api.org>
To
<BenzConsort-OC@listserve.api.org>,
<BenzConsort-TC@listserve.api.org>
cc
11/13/06 02:57
PM
Subject
Shanghai Health Study - new budget
estimate

Greetings,

Some OC members have asked for an estimate of individual company costs base

on Dr. Irons new budget estimates. Using the eleven shares formula (XOM and BP have 3 shares, Chevron and Shell have 2 shares, and ConocoPhillips has 1 share);

Finish study - \$5,759,864

1 share \$523,624

2 shares \$1,047,248

3 shares \$1,570,872

Finish study and transition lab - \$6,999,864

1 share \$636,351

2 shares \$1,272,703

3 shares \$1,909,054

Finish study, transition lab, and publish results - \$7,599,864

1 share \$690,897

2 shares \$1,381,793

3 shares \$2,072,690
